Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to.
16.01.2024 - Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share reflecting disciplined operating expense . Seite 1